We have recently shown that targeting a STRN-ALK rearrangement with an ALK-inhibitor in a patient with peritoneal mesothelioma, could lead to prolonged response [45] and Popat et al. presented a case with PTCH1 alteration where vismodegib treatment led to good response [65]. The gene discussed is ALK; the disease is peritoneal mesothelioma.